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Page 5 2009a; McIntyre et al., 2009b; McIntyre et al., 2010) have indicated that the therapeutic dose range of asenapine is 5 or 10 mg twice daily (BID).
The excretion balance (urinary and fecal) and the radioactivity concentrations in plasma were determined by LSC. Metabolite profiling was performed by HPLC with radioactivity detection. Isolation and purification of the metabolites was done by HPLC or SPE or liquid-liquid extraction. Identification of the metabolites, where feasible, was performed by comparison of retention time of authentic synthesized reference compounds, LC-MS-MS, and in some cases by NMR spectrometry or enzymatic deconjugation.
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Methods
Study execution and dose preparation and administration
The clinical part of this study was performed in the clinical research center of PRA (formerly Pharma Bio-Research), Zuidlaren, The Netherlands. Six healthy male volunteers (ages 21-54 years; body mass index, 20.5-28.1 kg/m 2 ) received sublingual unlabeled asenapine according to the schedule in Table 1 , which has previously been demonstrated to be well tolerated (Dogterom et al., 2009) . It was anticipated that healthy subjects would not tolerate an immediate single dose of 10 mg and therefore it was decided to gradually increase the dose, titrate to 10 mg and dose until steady state, which was expected after 6 days of dosing, before administration the radioactive dose. All doses were given BID except for the radioactive dose, which was administered as a single sublingual dose on the morning of day 10. Subjects were hospitalized from day -2 until 10 days after the final radioactive dose. Four subjects completed the study; two subjects withdrew before receiving the radioactive dose.
The study was approved by the appropriate medical ethics committee and conducted in full compliance with the declaration of Helsinki and the principles of Good Clinical
Practice. Laboratory assessments were performed in full compliance with Good Laboratory
Practice. All study participants signed an informed consent form before screening evaluations.
The radiolabeled asenapine sublingual tablets were prepared by dispensing
Bioanalysis
Bioanalysis of asenapine, N-desmethylasenapine, and asenapine-N-oxide in human plasma samples was performed by a validated assay using an internal standard method after SPE at the Department of Bioanalytics, Essex Pharma Development GmbH, Waltrop, Germany. For the main metabolite, asenapine N + -glucuronide, no standard was available at the time of bioanalysis.
The extracts were quantified by LC/MS using ES ionization in multireaction monitoring mode (data on file, 2008). Watson Drug Metabolism Laboratory Information
Management System (version 6.3.0.03) was used for all calculations. Calibration curves for asenapine, N-desmethylasenapine, and asenapine-N-oxide were constructed using linear weighted (1/x 2 ) regression.
Pharmacokinetics
All calculations were performed using SAS system for Windows Pharmacokinetic parameters were calculated from the plasma concentration-time data, where feasible.
Metabolite profiling, isolation and identification
Individual and pooled plasma samples were used for metabolite profiling and identification. Plasma samples containing sufficient radioactivity were analyzed individually This article has not been copyedited and formatted. The final version may differ from this version. Individual urine and fecal samples containing more than 5% of the administered radioactivity were selected for metabolite profiling. These urine and fecal samples were pooled per matrix and per individual in such way that quantification of metabolites reflects the situation in the excreta.
Sample treatment
Acidified (0.2% HCl, v/v %) plasma and urine samples were applied to pretreated The metabolic profiling of asenapine in pooled plasma, urine, and fecal samples was performed on an HP1100 liquid chromatograph (Agilent Technologies Deutschland GmbH, Waldbronn, Germany) equipped with a diode array detector using a µ-Bondapak C 18 column (internal diameter: 7.8 mm; internal length: 30 cm; particle size: 10 µm) and a gradient of ammonium acetate buffer (0.1 M, pH 4.2) (solvent A) and methanol/acetonitrile (1/3 v/v %) (solvent B) at 50°C. Elution started with 3 minutes isocratic at 10% solvent B followed by a linear gradient of 10%-40% solvent B in 17 minutes, 40%-90% solvent B in 30 minutes, and 90%-95% solvent B in 1 minute. This solvent composition was held during at least 3 minutes and maximally 8 minutes before returning to starting conditions. The flow rate was 2.0 mL/min.
Several reference compounds, monitored by UV detection (270 nm), were analyzed by HPLC, before or after analysis of the study samples. Radioactivity in the HPLC effluent was determined online using a flow-through detector (Flo-one\Beta model A500TR, PerkinElmer Life and Analytical Science, Zaventem, Belgium) or off-line by the collection of fractions followed by solid scintillation counting.
Isolation of metabolites
Pooled urine samples were filtered, acidified, and extracted by SPE. The eluate samples were concentrated and injected on HPLC, after which fractions were collected.
Fractions constituting a peak of radioactivity (U1-U10) were pooled and concentrated under a gentle stream of nitrogen gas. The isolated metabolite fractions were purified by SPE using Oasis HLB columns with acetonitrile/0.01 mol/L NH 4 OAc pH 4.2 (7/3 v/v %) and methanol/0.01% trifluoroacetic acid, respectively.
Fecal samples (homogenates) were pooled and extracted. The extracts were pooled, concentrated, and injected on HPLC, after which fractions were collected. Fractions
This article has not been copyedited and formatted. The final version may differ from this version. constituting a peak were pooled (F1-F11), concentrated, and further purified by acetonitrile/methanol/acetic acid extraction followed by extraction with diethylether.
On analysis, some of the fractions consisted of more metabolites, and attempts were made to purify these fractions using a variety of SPEs, liquid-liquid extractions, HPLC columns, elution profiles, and flow rates.
Hydrolysis of urinary metabolites
Metabolites U1 and U2/3, isolated from urine, were incubated in a solution containing sulphatase and ß-glucuronidase to identify the phase II (conjugated) metabolites. These metabolites were dried under a stream of nitrogen, dissolved in a drop of methanol/0.01% trifluoroacetic acid, and diluted with 0.1 mol·L -1 ammonium acetate buffer (pH 6).
Subsequently, these metabolites were incubated for 18 hours at 37 °C in the presence of sulphatase and ß-glucuronidase. In addition, incubation without sulphatase and ß-glucuronidase was performed as a control. Incubation mixtures were pretreated by SPE and subjected to HPLC analysis.
Identification of metabolites
A number of metabolites found in plasma, urine, and feces were tentatively identified by HPLC retention time comparison with authentic reference compounds and a previously 
NMR spectroscopy
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Plasma concentration of asenapine and total radioactivity
Mean plasma concentrations of asenapine plus metabolites expressed in ng equivalents/mL plasma were calculated from the total radioactivity concentrations in plasma samples and the specific activity of the 14 C-labeled formulated sublingual dose. The asenapine concentration in plasma was determined by bioanalysis.
Plasma concentrations of total radioactivity greatly exceeded those of asenapine from the first time point (0.5 h post-radioactive dosing) onward (Figure 2) . The peak concentration of [ 14 C]-radioactivity was reached 4 hours after dosing, later than for asenapine (0.75 h).
Half-lives (mean ± SD) of total radioactivity (39.3±7.6 h) and asenapine (27.5±5.0 h) in plasma were in the same range or slightly longer for the total radioactivity, suggesting that the metabolites of asenapine have a comparable or slightly longer half-life. The metabolites analyzed (N-desmethylasenapine and asenapine-N-oxide) constituted only a small fraction of the total of asenapine metabolites in plasma.
Excretion of radioactivity in urine and feces
After sublingual administration of [ 14 C]-asenapine to healthy male volunteers under steady-state conditions, radioactivity was excreted via urine and feces as shown in Figure 3 .
The cumulative excretion of radioactivity via urine was ~50%, whereas the cumulative excretion in feces was ~40%. The total recovery of radioactivity was ~90%: More than 80% of the radioactive dose was excreted within 96 hours.
Metabolite profiling and characterization
Radioactive peaks in the HPLC profiles were numbered per matrix on the basis of retention time. Asenapine was extensively and rapidly metabolized and resulted in several This article has not been copyedited and formatted. The final version may differ from this version. of circulating radioactivity was associated with conjugated metabolites. In addition, a significant percentage (~71%) of the excreted radioactivity was characterized. The most important MS-MS fragments and related metabolite structures of the identified metabolites in plasma, urine, and feces are given in Table 3 . The metabolic routes of asenapine are shown in Figure 4 .
Plasma
The metabolite profiles of pooled plasma samples (1 h and 1.5-12 h) consisted of at least 6 peaks (P1-P6). Peak P2/3 was the major metabolite in both pooled plasma samples.
Additionally, peak P6 was a major metabolite in the 1-hour pooled plasma sample. The metabolite profile of the 1.5-12 hour pooled plasma sample is given in Figure 5 .
P1: asenapine 11-O-sulphate
The HPLC retention time and LC-ES-MS spectra (m/z 382/384) of metabolite P1 eluting at 22.4 min were identical to the reference compound Org 214025-0 (asenapine 11-Osulphate). Based on LC/MS data, this peak also contained some other hydroxylated and 
Feces
The peaks present in fecal samples consisted of at least 11 different peaks (F1-F11), of which asenapine (F9, representing 5%-16% of the radioactive dose) was the major peak.
Additionally peak F1/2 (representing 6%-10% of the radioactive dose) and two minor peaks (F10 and F11) were isolated and identified. Peaks F3-F7 could not be further characterized.
Peak F8 coeluted with N-desmethylasenapine but was not further characterized. A representative metabolite profile is shown in Figure 7 (feces, 48-72 h, Subject 1). Mass balance resulted in a mean overall recovery of 93% of the administered radioactivity, of which >80% was excreted within 96 hours; excretion in the urine and feces accounted for 53% and 39%, respectively.
Plasma concentrations of total radioactivity greatly exceeded those of asenapine at any time point, indicating that asenapine is metabolized extensively and rapidly. Our results
showed that the asenapine-N + -glucuronide accounted for most of the radioactivity in plasma, followed by the N-desmethyl carbamoyl glucuronide. The three other radioactive detectable circulating compounds were asenapine, N-desmethylasenapine, and asenapine 11-hydroxysulphate. All other metabolites, as identified in urine and feces, were either not present or below the limit of radioactivity detection and/or identification. Asenapine-N-oxide was detected bioanalytically in some plasma samples (0.5 hours up to 1.5 hours post dosing) at very low levels (maximally, 0.2 ng·mL -1 ) but was below the limit of radioactivity detection in all plasma samples analyzed.
Pre-clinical data on file showed that the basic amine functionality is essential for the pharmacological activity of asenapine. Asenapine N + -glucuronide and N-desmethylasenapine have a diminished potency toward the receptors to which asenapine binds. While N-desmethyl-N-carbamoyl-asenapine glucuronide was not tested for activity, the fact that the nitrogen is no longer basic would lead to loss of binding activity. 11-hydroxy-asenapine sulphate was also tested and showed a similar receptor-binding profile as asenapine.
However, it was shown in the rat that this metabolite does not penetrate the brain. Other
This article has not been copyedited and formatted. The final version may differ from this version. putative metabolites that were tested for receptor activity included asenapine N-oxide, 11-hydroxyasenapine, and 7-hydroxy asenapine (data on file, 2008). These metabolites were below the limit of radioactivity detection in human circulation and thus it is unlikely that these metabolites contribute towards the pharmacological effects of asenapine. These data suggest that circulating human metabolites of asenapine do not contribute to the pharmacologic effects of asenapine.
Metabolites observed were mainly derived from reactions at the nitrogen in the fivemembered ring of asenapine. The primary route is direct glucuronidation. The main enzyme responsible for the direct glucuronidation of asenapine is UGT1A4 (data on file, 2008). The biotransformation of quaternary ammonium N + -glucuronidation has been characterized in humans for more than 30 drugs and xenobiotics, including antihistamines, antidepressants, and antipsychotics (Hawes, 1998) .
Glucuronidation is generally considered to be a pathway of detoxification, which commonly transforms lipophilic compounds into hydrophilic metabolites. Quaternary ammonium N + -glucuronides are not associated with toxicity. Asenapine N + -glucuronide is not suspected to cause any adverse effects because: (1) it would not be expected to be chemically reactive and is a stable compound; (2) it is not pharmacologically active and would not contribute to suprapharmacologic effects; (3) it is present to some extent in animal species used in safety assessments after administration of asenapine; and (4) asenapine is dosed maximally at 20 mg/day, resulting in low levels of circulating N + glucuronide (<1 µM).
Moreover, asenapine N + -glucuronide is of a class of metabolites that have been shown to be present in humans for other drugs at much greater levels than for asenapine (Hawes, 1998) .
Also important but apparently less pronounced is the demethylation pathway, followed by association with carbamic acid and conjugation with glucuronic acid, resulting in the N-desmethyl carbamoyl glucuronide. It is not unreasonable to propose that the carbamic This article has not been copyedited and formatted. The final version may differ from this version. several drugs containing a primary, secondary, or tertiary amine, the formation of a carbamic acid followed by a glucuronidation has been observed (Ronfeld et al., 1982; Straub et al., 1988; Brown et al., 1990; Delbressine et al., 1990; Obach et al., 2005; Obach et al., 2006; Schaeffer, 2006 ). An unprotonated primary or secondary amine and CO 2 are required to form a carbamic acid (Delbressine et al., 1990) , which was subsequently conjugated with the glucuronic acid (Schaeffer, 2006) . The formation of a carbamate glucuronide has been observed in excreta or the circulating system of several species, including humans, for several drugs, including tocainide (Ronfeld et al., 1982) , sertraline (Obach et al., 2005) , rimantadine (Brown et al., 1990) , and varenicline (Obach et al., 2006) . Some drugs that contained tertiary amines, for instance SK&F86466 (Straub et al., 1988) and mirtazapine (Delbressine et al., 1990) , are initially N-dealkylated to yield a secondary amine that is subsequently metabolized to a carbamate glucuronide. Metabolites observed in humans were also observed in laboratory animals at least on the basis of retention time comparison (data on file and van den Wildenberg et al., 1990) . In addition, all metabolic pathways as observed in human have been observed in preclinical species which confirm that the choice of preclinical species used in safety assessment was acceptable.
In summary, the overall disposition and metabolism of asenapine has been determined in male volunteers. Asenapine, after a single sublingual radiolabeled dose under steady-state conditions, is absorbed rapidly and substantially. Total excretion averaged 90% with excretion being slightly higher in urine than in feces. Metabolism appeared to be extensive and resulted in several regio-isomeric hydroxylated and conjugated metabolites. The metabolic reactions occurred mainly at the nitrogen, resulting in direct glucuronidated and This article has not been copyedited and formatted. The final version may differ from this version. 
